olaparib (Lynparza)

following a full submission assessed under the end of life and orphan equivalent medicine process:

olaparib (Lynparza®) is accepted for use within NHSScotland.

Indication under review: in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

In a phase III study, radiographic progression-free survival was significantly improved with the addition of olaparib to abiraterone plus prednisone or prednisolone compared with the addition of placebo in patients with mCRPC who had received no previous systemic therapy for metastatic disease.

This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.